Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

被引：31
|
作者：
LaCasce, Ann S. [1 ]
Bociek, R. Gregory [2 ]
Sawas, Ahmed [3 ]
Caimi, Paolo [4 ]
Agura, Edward [5 ]
Matous, Jeffrey [6 ]
Ansell, Stephen M. [7 ]
Crosswell, Howland E. [8 ]
Islas-Ohlmayer, Miguel [9 ]
Behler, Caroline [10 ]
Cheung, Eric [11 ]
Forero-Torres, Andres [12 ,13 ,15 ]
Vose, Julie [2 ]
O'Connor, Owen A. [3 ]
Josephson, Neil [13 ,15 ]
Wang, Yinghui [13 ]
Advani, Ranjana [14 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Columbia Univ, Med Ctr, New York, NY USA
[4] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[5] Charles A Sammons Canc Ctr, Dallas, TX USA
[6] Colorado Blood Canc Inst, Denver, CO USA
[7] Mayo Clin, Rochester, MN USA
[8] St Francis Hosp, Greenville, SC USA
[9] Jewish Hosp Mercy Hlth, Cincinnati, OH USA
[10] Pacific Hematol Oncol Associates, San Francisco, CA USA
[11] Oncol Inst Hope & Innovat, Whittier, CA USA
[12] Univ Alabama Birmingham, Birmingham, AL USA
[13] Seattle Genet Inc, Bothell, WA USA
[14] Stanford Canc Inst, Stanford, CA USA
[15] Zymeworks Biopharmaceut Inc, Bothell, WA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷 / 03期
关键词：
Hodgkin lymphoma; first salvage therapy; autologous stem cell transplantation; brentuximab vedotin; bendamustine; STEM-CELL TRANSPLANTATION; PHASE-II; CHEMOTHERAPY;
D O I：
10.1111/bjh.16499
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E86 / E90
页数：5
相关论文
共 50 条
  • [31] Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
    Thiruvengadam, Swetha Kambhampati
    Mei, Matthew G.
    Chen, Lu
    Puverel, Sandrine
    Chen, Robert
    Popplewell, Leslie L.
    Nikolaenko, Liana
    Peters, Lacolle
    Armenian, Saro
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10):
  • [32] Brentuximab vedotin plus bendamustine in relapsed and refractory classical Hodgkin lymphoma in children, adolescents and young adults: a single centre experience
    McMillan, A.
    O'Neill, A. T.
    Humphries, P.
    Lambert, J.
    Menezes, L.
    Shah, R.
    Townsend, W.
    Virchis, A.
    Von Both, K.
    Carpenter, B.
    Grandage, V.
    Hough, R.
    Ardeshna, K. M.
    Daw, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 99 - 99
  • [33] Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma
    Zsuzsa, Molnar
    Imre, Pinczes Laszlo
    Klara, Piukovics
    Ildiko, Istenes
    Krisztina, Wolf
    Zoltan, Csukly
    Arpad, Szomor
    Arpad, Illes
    Zsofia, Miltenyi
    ORVOSI HETILAP, 2017, 158 (41) : 1630 - 1634
  • [34] Brentuximab vedotin plus bendamustine in relapsed and refractory classical Hodgkin lymphoma in children, adolescents and young adults: a single centre experience
    McMillan, A.
    O'Neill, A. T.
    Humphries, P.
    Lambert, J.
    Menezes, L.
    Shah, R.
    Townsend, W.
    Virchis, A.
    Von Both, K.
    Ardeshna, K. M.
    Daw, S.
    KLINISCHE PADIATRIE, 2020, 232 (02): : 99 - 100
  • [35] Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents
    Martino, Massimo
    Festuccia, Moreno
    Fedele, Roberta
    Console, Giuseppe
    Cimminiello, Michele
    Gavarotti, Paolo
    Bruno, Benedetto
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (03) : 347 - 364
  • [36] Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
    A. Salihoglu
    T. Elverdi
    I. Karadogan
    S. Paydas
    E. Ozdemir
    G. Erdem
    N. Karadurmus
    G. Akyol
    L. Kaynar
    ZA Yegin
    G. Sucak
    V. Ozkocaman
    P. Topcuoglu
    M. Ozcan
    E. Birtas
    H. Goker
    Z. Baslar
    B. Ferhanoglu
    Annals of Hematology, 2015, 94 : 415 - 420
  • [37] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: EXPERIENCE IN TURKEY
    Ferhanoglu, B.
    Salihoglu, A.
    Elverdi, T.
    Karadogan, I.
    Ozdemir, E.
    Erdem, G.
    Karadurmus, N.
    Akyol, G.
    Kaynar, L.
    Yegin, A.
    Sucak, G.
    Ozkocaman, V.
    Topcuoglu, P.
    Ozcan, M.
    Birtas, E.
    Goker, H.
    Baslar, Z.
    Paydas, S.
    HAEMATOLOGICA, 2014, 99 : 675 - 676
  • [38] Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study
    Bouabdallah, Krimo
    Aubrais, Raphaelle
    Chartier, Loic
    Herbaux, Charles
    Banos, Anne
    Brice, Pauline
    Ochmann, Marlene
    Sibon, David
    De Colella, Jean Marc Schiano
    Cluzeau, Thomas
    Laribi, Kamel
    Le Calloch, Ronan
    Bellal, Mathieu
    Daguindau, Nicolas
    Amorim, Sandy
    Agbetiafa, Kossi
    Chauchet, Adrien
    Hammami, Marwa
    Durot, Eric
    Bonnet, Christophe
    Robles, Margot
    Fouillet, Ludovic
    Bijou, Fontanet
    Tournilhac, Olivier
    Gaulard, Philippe
    Parrens, Marie
    Milpied, Noel-Jean
    Damaj, Gandhi Laurent
    BLOOD, 2021, 138
  • [39] BRENTUXIMAB VEDOTIN PLUS HIGH-DOSE BENDAMUSTINE IS EFFECTIVE AND HAS A FAVOURABLE TOXICITY PROFILE IN THE TREATMENT OF REFRACTORY OR RELAPSED HODGKIN LYMPHOMA
    Cerchione, C.
    Picardi, M.
    Di Perna, M.
    Pugliese, N.
    Della Pepa, R.
    Pane, F.
    HAEMATOLOGICA, 2017, 102 : 107 - 107
  • [40] Nivolumab plus Brentuximab vedotin plus /- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
    Greve, Patrick
    Beishuizen, Auke
    Hagleitner, Melanie
    Loeffen, Jan
    Veening, Margreet
    Boes, Marianne
    Peperzak, Victor
    Diez, Claudius
    Meyer-Wentrup, Friederike
    FRONTIERS IN IMMUNOLOGY, 2023, 14
12345